Clinical trials: Gastric Adenocarcinoma
Gastric Adenocarcinoma
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e.
- Trial name
- FIDES-03 (NCT04604132)
- Testing
- Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
- Where
- 81 sites in United States, Argentina and 13 more
- Volunteers
- 47 people
- Sponsor
- Basilea Pharmaceutica
HER2, Advanced Gastric Cancer
Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy
The goal of this observational study is to learn about in describe treatment pattern and clinical outcomes in patients with HER2-overexpressed advanced solid tumors after progression of first-line standard therapy.
- Conditions
- HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05649163
- Testing
- Disitamab Vedotin
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Shen Lin
Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
For peritoneal metastatic gastric/gastroesophageal junction adenocarcinoma (cT3-4NanyM1), PD-1 antibody combined with chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) can downstage tumor stage, increase the…
- Conditions
- Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis
- Trial name
- NCT06914687
- Testing
- Tislelizumab, S-1, Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Gastric Cancer Stage
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
Investigators has conducted a series of studies on patient selection for perioperative immunotherapy in locally advanced gastric cancer.
- Trial name
- NCT07068516
- Testing
- Tislelizumab, SOX or CAPOX regimen
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Xiangdong Cheng
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational…
- Trial name
- NCT02551055
- Testing
- MLN1117, TAK-659, Alisertib
- Where
- 6 sites in United States, Spain
- Volunteers
- 32 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastric Adenocarcinoma, Gastric Cancer
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in…
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06038578
- Testing
- TRK-950, Ramucirumab, Paclitaxel
- Where
- 27 sites in United States, Japan and 1 more
- Volunteers
- 146 people
- Sponsor
- Toray Industries, Inc
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Gastric Adenocarcinoma, Gastric Cancer
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Gastric adenocarcinoma is the 4th most frequent cancer and the 2nd leading cause of cancer mortality. Most of the patients have metastatic, locally advanced or recurrent unresectable disease.
- Trial name
- NCT03959293
- Testing
- Durvalumab, Tremelimumab, FOLFIRI Protocol
- Where
- 35 sites in France
- Volunteers
- 107 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Hepatocellular Carcinoma, Liver Cirrhosis
Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC
Elasto-HCC is a prospective, uncontrolled, multicenter observational study involving several hepatology centers in Italy. Patients with liver cirrhosis and advanced hepatocellular carcinoma (HCC) who will need to undergo systemic…
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Portal Hypertension
- Trial name
- ELASTO-HCC (NCT06773260)
- Testing
- Liver and Spleen stiffness measurement.
- Where
- 12 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliero Universitaria Policlinico Modena
Stomach Adenocarcinoma
General Tissue Response Classification System After Chemotherapy
This research intend to collect the information of gastric cancer patients who received preoperative neoadjuvant chemotherapy and radical gastric ectomy at Department of Gastrointestinal Surgery, West China Hospital, Sichuan…
- Trial name
- NCT03791268
- Testing
- Gastric cancer surgery
- Where
- China
- Volunteers
- 200 people
- Sponsor
- West China Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult…
- Trial name
- NCT06196697
- Testing
- Cadonilimab, Ivonescimab, XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Harbin Medical University
Gastric Cancer
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a clinically relevant benefit for subjects with…
- Trial name
- EXPAND (NCT00678535)
- Testing
- Cetuximab, Capecitabine, Cisplatin
- Where
- 130 sites in Argentina, Australia and 23 more
- Volunteers
- 904 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- MiGIC (NCT07224750)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Advanced Gastric Carcinoma
Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection
Peri-operative treatment of locally advanced gastric cancer (LAGC) has always been argued by eastern and western scholars. For patients with clinical stage of cT4b/N+M0, or cT4aN+M0, the prognosis is rather poor, and the primary…
- Trial name
- NCT01534546
- Testing
- Oxaliplatin capecitabine, Oxaliplatin S-1
- Where
- 2 sites in China
- Volunteers
- 1,094 people
- Sponsor
- Peking University
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer.
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04220827
- Testing
- Paclitaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors, Gastric Cancer
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer
- Trial name
- NCT05275062
- Testing
- IM92 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01612546
- Testing
- cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Ovarian Neoplasms, Breast Neoplasms
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP).
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
- Trial name
- FiREBOLT (NCT07213791)
- Testing
- LY4337713
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.